



Contact: NeurOp Corporation
Vincent La Terza
Chief Executive Officer
Tel: (404) 343 4012
Email: laterza@neuropinc.com

NeurOp Opens Facilities & Adds Technical Staff

Atlanta, Georgia, September 25, 2006 – NeurOp Corporation, a preclinical stage pharmaceutical company focused on next generation drugs for CNS indications, announced that it has opened facilities at EmTech Bio, a biotech incubator located on the Emory University campus. The company also announced the addition of four scientists.

“NeurOp’s new facilities and the addition of seasoned, highly skilled technical staff, position the Company to make rapid progress. These new resources enable significant expansion in the medicinal chemistry and biological assay components of our discovery program,” explained Vincent La Terza, NeurOp’s CEO.

Dr. Scott Myers, NeurOp’s newly appointed Director of Drug Discovery has over 15 years of experience doing cutting edge research involving glutamate receptors and calcium channels, including a postdoctoral appointment in the lab of NeurOp founder Raymond Dingledine, Ph.D. “Scott possesses the unique combination of technical expertise, commitment and leadership we were looking for to spearhead the transition from the academic founders’ labs into our commercial operations. Scott is intimately familiar with all essential aspects of NeurOp’s pH sensitive NMDAR antagonists program,” observed Raymond Dingledine, Chairman of Emory University’s Department of Pharmacology.

A second key hire is Larry Wilson, Ph.D., NeurOp’s new Director of Medicinal Chemistry. Dr. Wilson earned his doctorate in the laboratory of Dennis Liotta, Ph.D., a renowned Emory medicinal chemist responsible for the discovery of several effective antiviral compounds. Dr. Wilson then spent 6 years doing preclinical medicinal chemistry at Proctor and Gamble and another 6 years at Johnson and Johnson. “Larry is a gifted synthetic chemist. His understanding of the process of lead optimization and how to navigate the path from final candidate through an Investigational New Drug application is an essential complement to the strong biological expertise of the NeurOp team. With their long-standing relationship with our founders, Scott and Larry carry forward the cohesion that has characterized the productive academic collaboration that has taken us to this juncture,” remarked CEO La Terza

Polina Lyuboslavsky joins NeurOp as a Discovery Scientist directly from the laboratory of NeurOp founder Steve Traynelis, Ph.D., Emory University Department of Pharmacology. “Ms. Lyuboslavsky has generated compelling screening and efficacy data for dozens of NeurOp’s lead compounds. Polina is exceptionally adept in working with challenging models of ischemia that require skillful animal surgery,” said Dr Myers. Rounding out the new staff is NeurOp technician Ms Elina Levin. Ms Levin recently graduated with honors from Emory with majors in Biology and Russian. “Elina is a quick study and is already performing key screening assays for the company,” commented Dr Myers.

About NeurOp, Inc.

NeurOp, Inc is a preclinical stage pharmaceutical company that is developing innovative therapeutics for CNS indications including, ischemia, pain and Parkinson’s disease. The company’s most advanced therapeutics modulate a well validated target, the NMDA receptor, in a novel manner designed to preserve therapeutic benefit while alleviating side effects associated with previous generation NMDAR antagonists. NeurOp was founded by three prominent neuroscientists: Dr. Raymond Dingledine, Professor and Chairman of the Department of Pharmacology at the Emory University School of Medicine; Dr. Steven Traynelis, Associate Professor in the Department of Pharmacology at Emory University and Dr James McNamara, Carl R. Deane Professor and Chairman of the Department of Neurobiology, Professor of Medicine (Neurology), and Director of the Center for Translational Neuroscience, Duke University Medical Center. NeurOp’s lead compounds have been synthesized in the laboratory of Dr Dennis Liotta, Ph.D. a professor in the Emory University Department of Chemistry. Dr Liotta is the inventor of several important antiviral compounds (e.g., Truvada, Gilead Sciences) and serves on the company’s Scientific Advisory Board.